ES2186907T3 - Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1. - Google Patents
Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1.Info
- Publication number
- ES2186907T3 ES2186907T3 ES97934217T ES97934217T ES2186907T3 ES 2186907 T3 ES2186907 T3 ES 2186907T3 ES 97934217 T ES97934217 T ES 97934217T ES 97934217 T ES97934217 T ES 97934217T ES 2186907 T3 ES2186907 T3 ES 2186907T3
- Authority
- ES
- Spain
- Prior art keywords
- neuropeptide
- bencilamine
- substituted
- new class
- specific ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA INVENCION ABARCA COMPUESTOS DE FORMULA (I) Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE X 1 , X SUB,2 , X 3 REPRESENTAN SUSTITUYENTES INORGANICOS U ORGAN ICOS; N ES 1, 2 O 3; M ES 2, 3 O 4, R 1 - R 4 SON HIDROGENO O SUSTITUYENTES ORGANICOS; Y B ES NITROGENO, CARBONO, AZUFRE U OXIGENO. DICHOS COMPUESTOS SON UTILES EN EL DIAGNOSTICO Y TRATAMIENTO DE ALTERACIONES DE LA ALIMENTACION COMO LA OBESIDAD Y LA BULIMIA, Y DE ENFERMEDADES CARDIOVASCULARES, COMO LA HIPERTENSION ARTERIAL ESENCIAL Y LA INSUFICIENCIA CARDIACA GLOBAL, DEBIDO A LA FIJACION DE DICHOS COMPUESTOS A LOS RECEPTORES DE NEUROPEPTIDOS Y1 DE ORIGEN HUMANO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2229696P | 1996-07-23 | 1996-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2186907T3 true ES2186907T3 (es) | 2003-05-16 |
Family
ID=21808865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97934217T Expired - Lifetime ES2186907T3 (es) | 1996-07-23 | 1997-07-18 | Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1. |
Country Status (8)
Country | Link |
---|---|
US (1) | US5962455A (es) |
EP (1) | EP0915859B1 (es) |
JP (1) | JP2000515150A (es) |
AT (1) | ATE230403T1 (es) |
CA (1) | CA2261031A1 (es) |
DK (1) | DK0915859T3 (es) |
ES (1) | ES2186907T3 (es) |
WO (1) | WO1998003492A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2197354T3 (es) | 1996-07-23 | 2004-01-01 | Neurogen Corporation | Derivados de bencilamina sustituidos con amido y amino; una nueva clase de ligandos especificos del neuropeptido y1. |
US6693130B2 (en) * | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
DE60014603T2 (de) * | 1999-03-12 | 2006-02-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
IL139457A0 (en) * | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
WO2001053477A1 (en) * | 2000-01-20 | 2001-07-26 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US7526122B2 (en) * | 2001-07-12 | 2009-04-28 | Sony Corporation | Information inputting/specifying method and information inputting/specifying device |
EP2002827A2 (en) | 2001-12-05 | 2008-12-17 | The Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
JP4943837B2 (ja) | 2003-04-03 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良インヒビター |
ATE462432T1 (de) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Glutaminylcyclase-hemmer |
CA2533112A1 (en) | 2003-08-13 | 2005-03-03 | Christopher Hulme | Melanin concentrating hormone receptor antagonist |
AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
BRPI0507485A (pt) | 2004-02-05 | 2007-07-10 | Probiodrug Ag | inibidores novos de glutaminil ciclase |
EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
SG149027A1 (en) | 2004-06-17 | 2009-01-29 | Cytokinetics Inc | Substituted urea derivatives for treating cardiac diseases |
ZA200703613B (en) | 2004-10-20 | 2009-05-27 | Univ California | Improved inhibitors for the soluble epoxide hydrolase |
EP1804785A2 (en) * | 2004-10-27 | 2007-07-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
NZ556163A (en) * | 2005-01-10 | 2011-11-25 | Univ California | Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors |
WO2007070683A2 (en) | 2005-12-15 | 2007-06-21 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
EP1834953A1 (en) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
JP2010507587A (ja) * | 2006-10-20 | 2010-03-11 | アレテ セラピューティクス, インコーポレイテッド | 可溶性エポキシドヒドロラーゼ阻害剤 |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
ES2533484T3 (es) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
DK2475428T3 (en) | 2009-09-11 | 2015-09-28 | Probiodrug Ag | Heterocyclic derivatives as glutaminylcyklaseinhibitorer |
EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
DE69033100T2 (de) * | 1989-04-22 | 2000-01-05 | Wyeth John & Brother Ltd | Piperazin-Derivate |
SK57097A3 (en) * | 1994-11-07 | 1998-10-07 | Pfizer | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
IL117997A0 (en) * | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
-
1997
- 1997-07-18 CA CA002261031A patent/CA2261031A1/en not_active Abandoned
- 1997-07-18 EP EP97934217A patent/EP0915859B1/en not_active Expired - Lifetime
- 1997-07-18 JP JP10507101A patent/JP2000515150A/ja not_active Ceased
- 1997-07-18 AT AT97934217T patent/ATE230403T1/de not_active IP Right Cessation
- 1997-07-18 ES ES97934217T patent/ES2186907T3/es not_active Expired - Lifetime
- 1997-07-18 US US08/897,045 patent/US5962455A/en not_active Expired - Fee Related
- 1997-07-18 DK DK97934217T patent/DK0915859T3/da active
- 1997-07-18 WO PCT/US1997/012614 patent/WO1998003492A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO1998003492A1 (en) | 1998-01-29 |
JP2000515150A (ja) | 2000-11-14 |
EP0915859B1 (en) | 2003-01-02 |
ATE230403T1 (de) | 2003-01-15 |
US5962455A (en) | 1999-10-05 |
DK0915859T3 (da) | 2003-03-03 |
CA2261031A1 (en) | 1998-01-29 |
EP0915859A1 (en) | 1999-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2186907T3 (es) | Ciertos derivados de bencilamina sustituidos; una nueva clase de ligandos especificos del neuropeptido y1. | |
NO972091L (no) | Bestemte substituerte benzylaminderivater; en ny klasse nouropeptid-yl-spesifikke ligander | |
ATE98245T1 (de) | Azaindene. | |
IS6257A (is) | Frumuviðloðunartálmar | |
DE60129806D1 (de) | Neue bizyklische verbindungen | |
HUP0401837A2 (hu) | Dikarbonsavszármazékok, előállításuk és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
DK1204654T3 (da) | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister | |
DE69820632D1 (de) | 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate | |
FI924397A (fi) | Substituerade pyrimidiner | |
TR200100238T2 (tr) | Yeni sübstitüe edilmiş pirazol türevleri | |
ATE239003T1 (de) | Dibenzothiophene derivate und ihre verwendung | |
MY110142A (en) | Thiazolidinedione derivatives, their production and use | |
DE60020873D1 (de) | Nervonsäurederivate,ihre herstellung und anwendung | |
DE60012751D1 (de) | Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz | |
CY1105734T1 (el) | Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων | |
ATE311383T1 (de) | Nicht-peptidische bombesin rezeptor antagonisten | |
TR200201684T2 (tr) | Fenilpiperazinil türevleri | |
PT1392306E (pt) | Tetra-hidroisoquinolinas substituídas para utilização no tratamento de doenças inflamatórias | |
ATE237585T1 (de) | Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung | |
HUP9800649A2 (hu) | Benzil-oxi-csoporttal helyettesített, kondenzált N-heterociklusos vegyületek, eljárás előállításukra és alkalmazásuk bradikinin receptorantagonistaként | |
EA200101234A1 (ru) | Новые производные аминотиазола, их получение и содержащие их фармацевтические композиции | |
BR0009582A (pt) | Composto, composição farmacêutica, e, processopara o tratamento de uma condição de doençaselecionada de artrite reumatóide, doença dealzheimer, câncer, esquizofrenia, edema, rinitealérgica, inflamação, dor, hipermobilidadegastrointestinal , asma gástrica, refluxogastroesfageal, ansiedade, emese, doença dehuntington, psicoses incluindo depressão,hipertensão, enxaqueca e urticária | |
EA200200727A1 (ru) | Новые производные индола | |
NO895222D0 (no) | Fremgangsmaate for fremstilling av n-pyridinyl-9h-karbazol-9-aminer. | |
MX9709980A (es) | Ciertos derivados de bencilamina sustituidos: una nueva clase de ligandos especificos del neuropeptido y1. |